Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Stay Ahead of the Market:Discover outperforming stocks and invest ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure with future uncertainties.

Hims & Hers Health (HIMS) is down more than -3% after Citigroup downgraded the stock to sell from neutral with a price target of $25. ON Semiconductor (ON) is down more than -3% after Truist ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.

The US 10-year T-note yield soared to a 14-month high, the 10-year German bund yield climbed to a 6-month high, and the Japanese 10-year JGB yield rose to a 13-year high.  Stocks are sinking today on ...